Drs Ursula A. Matulonis and Alexi A. Wright discuss survivorship issues in endometrial cancer including sexual dysfunction, mental health, fatigue, and peripheral neuropathy.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999849. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Cancer Survivorship Guidelines https://emedicine.medscape.com/article/2500027-overview

Patterns and Predictors of Cancer-Related Fatigue in Ovarian and Endometrial Cancers: 1-Year Longitudinal Study https://pubmed.ncbi.nlm.nih.gov/32436610/

Research Status of Internet-Delivered Cognitive Behavioral Therapy in Cancer Patients https://pubmed.ncbi.nlm.nih.gov/38073902/

Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/28253393/

Pilot Randomized Trial of an Acceptance-Based Telehealth Intervention for Women With Ovarian Cancer and PARP Inhibitor-Related Fatigue https://pubmed.ncbi.nlm.nih.gov/37708581/

Improvements Following Multimodal Pelvic Floor Physical Therapy in Gynecological Cancer Survivors Suffering From Pain During Sexual Intercourse: Results From a One-Year Follow-Up Mixed-Method Study https://pubmed.ncbi.nlm.nih.gov/35077479/

Mismatch Repair Deficiency and Clinicopathological Characteristics in Endometrial Carcinoma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/33845554/

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016 https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm

US Trends in Opioid Access Among Patients With Poor Prognosis Cancer Near the End-of-Life https://pubmed.ncbi.nlm.nih.gov/34292766/

Enhanced Recovery After Surgery (ERAS): A Perspective Review of Postoperative Pain Management Under ERAS Pathways and Its Role on Opioid Crisis in the United States https://pubmed.ncbi.nlm.nih.gov/31868759/

Drs Ursula A. Matulonis and Kathleen N. Moore discuss the different aspects of antibody-drug conjugates (ADCs) in endometrial cancer, medications that are currently available, and promising HER2 ADCs.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/999848. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Uterine Neoplasms Version 2.2024 — March 6, 2024 https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf

DESTINY-PanTumor-02: Trastuzumab Deruxtecan Has Activity Against a Range of HER2-Expressing Solid Tumors https://dailynews.ascopubs.org/do/destiny-pantumor-02-trastuzumab-deruxtecan-has-activity-against-range-her2-expressing

LBA34 - Trastuzumab Deruxtecan (T-DXd) for Pretreated Patients (pts) With HER2-Expressing Solid Tumors: Primary Analysis From the DESTINY-PanTumor02 (DP-02) Study https://oncologypro.esmo.org/meeting-resources/esmo-congress/trastuzumab-deruxtecan-t-dxd-for-pretreated-patients-pts-with-her2-expressing-solid-tumors-primary-analysis-from-the-destiny-pantumor02-dp-02

Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33934848/

A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gy026?filter=nrg-gy026

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10730032/

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology https://pubmed.ncbi.nlm.nih.gov/27841667/

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial https://pubmed.ncbi.nlm.nih.gov/36977309/

A Study of DB-1303 in Advanced/Metastatic Solid Tumors https://clinicaltrials.gov/study/NCT05150691

DNA Mismatch Repair Proteins: Scientific Update and Practical Guide https://pubmed.ncbi.nlm.nih.gov/33597222/

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) https://clinicaltrials.gov/study/NCT04209855

PRO1184 for Advanced Solid Tumors (PRO1184-001) https://www.clinicaltrials.gov/study/NCT05579366

A New Wave of Innovations Within the DNA Damage Response https://pubmed.ncbi.nlm.nih.gov/37679326/

Center for DNA Damage and Repair https://www.dana-farber.org/research/integrative-research/dna-damage-and-repair

The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions https://pubmed.ncbi.nlm.nih.gov/33806979/

Genomic Landscape of Endometrial Carcinomas of No Specific Molecular Profile https://pubmed.ncbi.nlm.nih.gov/35365770/

The Emerging Genomic Landscape of Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/24170611/